Eupraxia's Highest-Dose Cohort Shows Sustained EoE Remission in Phase 1b/2a Trial
Event summary
- Eupraxia's highest-dose cohort (20 x 8 mg) in the RESOLVE trial showed 90% reduction in EoEHSS Stage and 88% reduction in Grade at 36 weeks.
- 66% of patients in Cohort 9 maintained clinical remission from weeks 8 to 36.
- No drug-related serious adverse events reported across 31 patients and 230 patient-months of follow-up.
- Phase 2b placebo-controlled portion of the RESOLVE trial is recruiting, with top-line data expected in Q4 2026.
The big picture
Eupraxia's positive Phase 1b/2a data for EP-104GI in eosinophilic esophagitis (EoE) underscores the potential of its Diffusphere™ technology to deliver sustained, localized drug effects. The absence of serious adverse events and the maintained remission rates in the highest-dose cohort position the company favorably as it prepares for the pivotal Phase 2b trial. With EoE affecting over 450,000 people in the U.S., the successful development of EP-104GI could address a significant unmet need in inflammatory gastrointestinal diseases.
What we're watching
- Clinical Efficacy
- Whether the sustained remission rates in the highest-dose cohort will translate to statistically significant results in the placebo-controlled Phase 2b trial.
- Regulatory Pathway
- The pace at which Eupraxia can advance EP-104GI through subsequent clinical phases given the positive safety and efficacy data.
- Market Potential
- How Eupraxia's Diffusphere™ technology could expand into other therapeutic areas beyond EoE and osteoarthritis.
Related topics